Seqster, the award-winning SaaS-based technology platform enabling consumer-centered health data management, today announced a 3-year licensing deal and partnership with La Jolla Institute of Immunology (LJI) to support the execution of a $6.9...
22-Oct-2019 11:30 AM EDT Add to Favorites
A new study, led by researchers at La Jolla Institute for Immunology (LJI), identified and then reverse engineered the molecular properties shared by antibodies that are particularly efficient at inactivating or “neutralizing” Lassa virus...
5-Aug-2019 8:05 AM EDT Add to Favorites
In their latest study, published in this week’s online issue of Proceedings of the National Academy of Sciences, researchers at La Jolla Institute for Immunology (LJI), reveal how the finely tuned balance between DNA methylation and demethylation...
24-Jul-2019 2:45 PM EDT Add to Favorites
In a new study, published on June 25, 2019, in the journal eLife, the researchers report that higher levels of doublets can be found in people with severe cases of tuberculosis or dengue fever.
24-Jun-2019 5:05 PM EDT Add to Favorites
Tissue-resident memory T cells (TRMs) are known to help the body fight infection, but they are also key tumor fighters. A new study reveals that these cells are unique in their ability to seek out and kill tumor cells without suffering from the...
21-Jun-2019 5:05 PM EDT Add to Favorites
Eric Zwisler, former President and Chairman of Cardinal Health China, has been elected Chairman of the Board of Directors of La Jolla Institute for Immunology. He will assume his role effective May 31, 2019.
3-Jun-2019 3:05 PM EDT Add to Favorites
NIH awards $35 million grant to establish global Consortium to develop treatments for Ebola, Lassa and other viral threats
La Jolla Institute Professor Erica Ollmann Saphire, Ph.D., will lead a five-year global effort totaling up to $35 million that brings together experts from around the world to streamline and accelerate the development of immunotherapeutics against...
27-May-2019 12:05 PM EDT Add to Favorites
A decade ago researchers announced development of a cancer immunotherapy called CAR (for chimeric antigen receptor)-T, in which a patient is re-infused with their own genetically modified T cells equipped to mount a potent anti-tumor attack.
23-May-2019 4:05 AM EDT Add to Favorites
see all news
Dr. Matthias von Herrath, M.D., who founded the Type 1 Diabetes Center at La Jolla Institute for Immunology (LJI) has been identified as the world’s top expert in Type 1 Diabetes by Expertscape, an organization that provides tools to quickly and...
12-Dec-2018 11:05 AM EST